FAKTOR YANG BERHUBUNGAN DENGAN HIPOGLIKEMIA PADA PASIEN DIABETES MELITUS TIPE 2 YANG MENGGUNAKAN SULFONILUREA: LITERATURE REVIEW

Sulfonylureas remain widely prescribed for type 2 diabetes mellitus (T2DM), yet their use is strongly associated with hypoglycemia leading to emergency department visits, hospitalization, impaired awareness of hypoglycemia (IAH), and mortality. Available primary studies encompass heterogeneous study designs and populations ranging from dedicated sulfonylurea cohorts to mixed antidiabetic regimens. To identify and synthesize factors associated with hypoglycemia in T2DM patients treated with sulfonylureas. This literature review followed the PRISMA 2020 reporting flow via a structured PubMed search for English-language articles published between January 2016 and October 2026 (search conducted on October 15, 2026). Out of 121 identified records, two reviewers independently performed dual title/abstract screening and assessed 46 full-text articles for eligibility, yielding 17 included studies (13 Direct SU Evidence studies and 4 Mixed-Treatment Evidence studies). Methodological quality was appraised using Joanna Briggs Institute (JBI) Critical Appraisal Checklists, and data were synthesized narratively without meta-analysis due to heterogeneity across study designs and hypoglycemia outcome definitions. JBI appraisal rated 16 studies as high quality and 1 pilot study as moderate quality. Factors consistently associated with increased hypoglycemia included: (1) patient factors: older age (≥ 65 to ≥ 75 years; aIRR = 2.41; 95% CI 1.69–3.44), Black Caribbean (aIRR = 1.63), Black African (aIRR = 1.90), and Indian (aIRR = 1.93) ethnicity, cognitive impairment, and lack of structured diabetes education; (2) clinical factors: prior hypoglycemia hospitalization (aOR = 16.44; 95% CI 1.74–154.33), tight glycemic control with HbA1c < 7.0% in SU cohorts (aHR = 1.54; 95% CI 1.27–1.87) and adults aged ≥ 70 years on SU/insulin (aHR = 2.52; 95% CI 2.23–2.84), and impaired renal function (eGFR < 30 mL/min/1.73 m²); (3) treatment factors: second-line addition/switching to SUs (aHR = 7.60; 95% CI 4.64–12.44), metformin + SU versus DPP-4 inhibitors (aHR = 2.07; 95% CI 1.61–2.66), long-acting pancreas-nonspecific SUs (glyburide/glimepiride) versus short-acting pancreas-specific SUs (gliclazide/glipizide/tolbutamide) (aHR = 2.83; 95% CI 1.64–4.88), and SU duration ≥ 5 years for IAH (aOR = 3.06–3.56); and (4) concomitant drug interactions with amiodarone (weighted HR = 1.92; 95% CI 1.12–3.30) or warfarin (aHR = 1.38; 95% CI 1.10–1.75). Conversely, metabolic markers (low basal β-cell function HOMA-2%β [aIRR = 1.74] and elevated fasting insulin [ρ = 0.390]) showed exploratory associations, whereas CYP2C9 (2/3; aOR = 0.80; p = 0.30), KCNJ11, and ABCC8 variants showed no significant association. Hypoglycemia in T2DM patients using sulfonylureas is associated with a multidomain interplay of patient, clinical, treatment, and drug-interaction factors, with varying strength of evidence across study designs.

Authors

Institutions

Publication Details

Journal
Journal of Health and Nursing.
Published
2026-11-19
DOI
https://doi.org/10.58738/jhn.v4i2.2015
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FAKTOR YANG BERHUBUNGAN DENGAN HIPOGLIKEMIA PADA PASIEN DIABETES MELITUS TIPE 2 YANG MENGGUNAKAN SULFONILUREA: LITERATURE REVIEW

Mally Ghinan Sholih, Rahmawati Azara Putri, Eca Enjiska
Journal of Health and Nursing.
Diabetes Treatment and Management
article

FAKTOR YANG BERHUBUNGAN DENGAN HIPOGLIKEMIA PADA PASIEN DIABETES MELITUS TIPE 2 YANG MENGGUNAKAN SULFONILUREA: LITERATURE REVIEW

Mally Ghinan Sholih, Rahmawati Azara Putri, Eca Enjiska
article en

Abstract

Sulfonylureas remain widely prescribed for type 2 diabetes mellitus (T2DM), yet their use is strongly associated with hypoglycemia leading to emergency department visits, hospitalization, impaired awareness of hypoglycemia (IAH), and mortality. Available primary studies encompass heterogeneous study designs and populations ranging from dedicated sulfonylurea cohorts to mixed antidiabetic regimens. To identify and synthesize factors associated with hypoglycemia in T2DM patients treated with sulfonylureas. This literature review followed the PRISMA 2020 reporting flow via a structured PubMed search for English-language articles published between January 2016 and October 2026 (search conducted on October 15, 2026). Out of 121 identified records, two reviewers independently performed dual title/abstract screening and assessed 46 full-text articles for eligibility, yielding 17 included studies (13 Direct SU Evidence studies and 4 Mixed-Treatment Evidence studies). Methodological quality was appraised using Joanna Briggs Institute (JBI) Critical Appraisal Checklists, and data were synthesized narratively without meta-analysis due to heterogeneity across study designs and hypoglycemia outcome definitions. JBI appraisal rated 16 studies as high quality and 1 pilot study as moderate quality. Factors consistently associated with increased hypoglycemia included: (1) patient factors: older age (≥ 65 to ≥ 75 years; aIRR = 2.41; 95% CI 1.69–3.44), Black Caribbean (aIRR = 1.63), Black African (aIRR = 1.90), and Indian (aIRR = 1.93) ethnicity, cognitive impairment, and lack of structured diabetes education; (2) clinical factors: prior hypoglycemia hospitalization (aOR = 16.44; 95% CI 1.74–154.33), tight glycemic control with HbA1c < 7.0% in SU cohorts (aHR = 1.54; 95% CI 1.27–1.87) and adults aged ≥ 70 years on SU/insulin (aHR = 2.52; 95% CI 2.23–2.84), and impaired renal function (eGFR < 30 mL/min/1.73 m²); (3) treatment factors: second-line addition/switching to SUs (aHR = 7.60; 95% CI 4.64–12.44), metformin + SU versus DPP-4 inhibitors (aHR = 2.07; 95% CI 1.61–2.66), long-acting pancreas-nonspecific SUs (glyburide/glimepiride) versus short-acting pancreas-specific SUs (gliclazide/glipizide/tolbutamide) (aHR = 2.83; 95% CI 1.64–4.88), and SU duration ≥ 5 years for IAH (aOR = 3.06–3.56); and (4) concomitant drug interactions with amiodarone (weighted HR = 1.92; 95% CI 1.12–3.30) or warfarin (aHR = 1.38; 95% CI 1.10–1.75). Conversely, metabolic markers (low basal β-cell function HOMA-2%β [aIRR = 1.74] and elevated fasting insulin [ρ = 0.390]) showed exploratory associations, whereas CYP2C9 (2/3; aOR = 0.80; p = 0.30), KCNJ11, and ABCC8 variants showed no significant association. Hypoglycemia in T2DM patients using sulfonylureas is associated with a multidomain interplay of patient, clinical, treatment, and drug-interaction factors, with varying strength of evidence across study designs.

Journal of Health and Nursing.Vol. 4(2)
University of Singaperbangsa Karawang (ID)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon